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Abstract － Clinical cases of pure red cell aplasia (PRCA) have been reported during the recombinant 
human erythropoietin (EPO) therapy for the anemia patients. PRCA is a rare hematological disorder leading 
to a severe anemia due to an almost complete stop of red blood cell production. Antibody (Ab)-associated 
PRCA is caused by the EPO-neutralizing Abs that eliminate the biological activity of EPO. In order to detect 
anti-EPO Abs in human sera, we performed conventional ELISA, directly coated bridging ELISA, and 
streptavidin coated bridging ELISA, and compared their sensitivity and specificity. Some false positive results 
were obtained in the conventional ELISA. One positive sample was detected successfully by streptavidin 
coated bridging ELISA, which was not appeared in the directly coated bridging ELISA. In conclusion, 
streptavidin coated bridging ELISA was substantially sensitive and specific format and one out of sixty-eight 
serum samples was proved to be anti-EPO positive.
Keywords: Erythropoietin, Pure red-cell aplasia, Bridging ELISA, Immunogenicity
INTRODUCTION
    Human erythropoietin (EPO) produced in the kidney is a 
heavily glycosylated protein that enhancing red blood cell 
production in the bone marrow. Chronic kidney disease 
(CKD) patients suffer from anemia caused by reduced 
EPO production. To treat anemia of CKD patients, re-
combinant EPO protein has been used successfully since 
1988 (Erslev and Besarab, 1997; Bennett et al., 2004). 
However, neutralizing anti-EPO Abs and pure red cell 
aplasia (PRCA) caused by these Abs have been reported 
in some EPO-treated patients (Casadevall et al., 2002). 
PRCA is a rare hematological disorder leading to a severe 
anemia due to an extremely decreased production of red 
blood cell. EPO-associated PRCA is occurred by anti-EPO 
neutralizing Abs depriving of the activity of endogenous 
and exogenous EPO (Casadevall et al., 1996; Casadevall 
et al., 2002) and this cases have recently been increased 
in Europe (Casadevall et al., 2002; Gershon et al., 2002; 
Bennett et al., 2004; Tolman et al., 2004).
    The identification of anti-EPO Abs is the key to diagnose 
EPO-associated PRCA and several assays have been de-
veloped and used for this. Enzyme-linked immunosorbent 
assay (ELISA) (Kientsch-Engel et al., 1989; Urra et al., 
1997; Hoesel et al., 2004; Swanson et al., 2004), radio-
immunoprecipitation (RIP) (Casadevall et al., 2002; Tacey 
et al., 2003), and surface plasmon resonance (SPR) 
(Swanson, 2003) have been used to detect the presence 
of anti-EPO Abs and in vitro bioassays are used to meas-
ure the neutralizing activity of anti-EPO Abs. However, cur-
rently, there are no standard assays to compare data from 
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different worldwide labs owing to absence of appropriate 
biological standards for assay validation and calibration.
    Conventional ELISA for detection of anti-EPO Abs was 
developed (Urra et al., 1997). Plates were coated with 
EPO at 10 ug/ml and added with diluted serum from a 
EPO-resistant hemodialysis patient. Subsequently, horse-
radish peroxidase (HRP)-conjugated goat anti-human IgG 
or IgM was added and color was developed by tetrame-
thylbenzidine substrate. Anti-EPO IgG Abs were detected 
from the single patient and no Abs from normal controls. 
This ELISA was rapid, easy to use, and inexpensive. How-
ever, it has some disadvantages such as non-specific ma-
trix effects, alteration of EPO conformation and epitope 
masking by immobilization process (Thorpe and Swanson, 
2005a). 
    Directly coated bridging ELISA was developed (Swan-
son et al., 2004). Anti-EPO Abs in patient serum bridge bi-
otinylated EPO to EPO immobilized to a plate well. Subse-
quently, streptavidin-HRP was added and color was devel-
oped by tetramethylbenzidine substrate. This ELISA was 
highly specific due to dual arm binding, however, immobili-
zation process may alter the EPO conformation and biotin 
labeling of EPO is required (Thorpe and Swanson, 2005a).
    Streptavidin coated bridging ELISA was developed and 
validated (Hoesel et al., 2004; Gross et al., 2006; Gross et 
al., 2008). Anti-EPO Abs in patient serum bridge digox-
igenylated EPO to biotinylated EPO immobilized to a strep-
tavidin coated-plate well. Subsequently, anti-digoxigenin 
(DIG) Fab-HRP conjugate was added and color was devel-
oped by ABTS substrate. This ELISA was very sensitive (a 
lower limit of detection is 1 ng/ml), specific (no back-
grounds in normal serum samples) and suitable for screen-
ing large numbers of samples. Epitope masking or con-
formation change of EPO by immobilization to plate was 
overcome by the use of streptavidin to capture biotinylated 
EPO in this ELISA.
    As described, there are some ELISA formats to detect 
anti-EPO Abs and they have some advantages and dis-
advantages. In this study, we applied three kinds of ELISAs 
in order to adopt the most suitable assay to screen anti- 
EPO Abs in the human serum. Sixty-eight numbers of 
samples from CKD patients were analyzed and one sam-
ple was proved to be positive for anti-EPO Abs. Interaction 
between EPO and Abs in positive sample was confirmed 
by protein A/G pull down and western blot.
    Our results suggest that among ELISA methods, strep-
tavidin coated bridging ELISA is currently the most suitable 
assay for detection of anti-EPO Abs in human sera.
MATERIALS AND METHODS
Conventional ELISA
    ELISA plates (Maxisorp, Nunc Inc., Copenhagen, 
Denmark) were coated with 1 μg/ ml of EPO in phosphate 
buffered saline (PBS, Amresco Inc., Solon, OH, USA). 
After incubation overnight at 4oC, the plates were blocked 
with PBSA (PBS, 1% BSA) for 1 h at room temperature 
(RT). After washing with PBST (PBS, 0.05% Tween-20), 
serum samples were diluted at 1:50 with PBSAT (PBS, 1% 
BSA, 0.05% Tween-20) and added to each well and in-
cubated for 1 h at RT. Bound Ab was detected with HRP 
conjugated sheep anti-human IgG (Millipore Inc., Billerica, 
MA, USA). After washing, ABTS solution (Roche, Mannheim, 
Germany) was added to each well and incubated. Optical 
density was measured at 405 nm (reference wavelength: 
492 nm) by Versamax microplate reader (Molecular 
Devices Inc., Sunnyvale, CA, USA).
Biotinylation of EPO
    Biotin was labeled to EPO with EZ-LinkⓇ Sulfo-NHS- 
LC-Biotinylation Kit (Pierce Inc., Rockford, IL, USA) ac-
cording to the manufacturer’s protocol. In brief, 10 mM 
Sulfo-NHS-LC-Biotin was dissolved in PBS and mixed with 
1 mg of EPO for 2 hours on ice. A ZebaTM desalt spin col-
umn was used to exchange buffer and remove excess bio-
tin reagent. The level of biotin incorporation was measured 
by HABA assay. Protein concentration was determined by 
DC Protein Assay (Biorad Inc., Hercules, CA, USA).
Directly coated bridging ELISA
    ELISA plates were coated with 1 μg/ml of EPO in PBS. 
After incubation overnight at 4oC, the plates were blocked 
with PBSA for 1 h at RT. After washing with PBST, 1:5 di-
luted serum samples were mixed with an equal volume of 
300 ng/ml of biotinylated-EPO (BIO-EPO) in PBSAT and 
this mixture was added to wells and incubated for 2 hours 
at RT. After incubation, plates were washed 3 times and 
streptavidin-HRP conjugate (Thermo scientific Inc., Rockford, 
IL, USA) diluted in PBSAT was added to each well and 
then incubated for 1 hour. After washing, ABTS solution 
was added to each well and incubated. Optical density was 
measured at 405 nm (reference wavelength: 492 nm). 
Rabbit polyclonal anti-EPO Ab (H-162, Santa Cruz bio-
technology, Santa Cruz, CA, USA) was used as positive 
control.
Digoxigenylation of EPO
    Digoxigenin-3-O-methylcarbonyl-aminocaproic acid-N- 
hydroxysuccinimide ester (DIG, Roche, Mannheim, Germany) 
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Fig. 1. Screening of serum samples with conventional ELISA. ELISA plates were coated with 1 μg/ml of EPO. The plates were blocked
and serum samples diluted at 1:50 were added. Bound Ab was detected with HRP conjugated sheep anti-human IgG and ABTS 
solution was added to each well and incubated. Optical density was measured at 405 nm (reference wavelength: 492 nm). NC is for 
normal control and BK is for blank.
was labeled to EPO according to the manufacturer’s 
protocol. In brief, 5 mg of DIG was dissolved in DMSO and 
incubated with 0.5 mg of EPO dissolved in PBS, pH 8.5, for 
2 hours at room temperature (RT). A MicroconⓇ Centrifu-
gal Filter Units (Millipore, Billerica, MA, USA) was used to 
exchange buffer and remove excess DIG reagent. Protein 
concentration was determined by DC Protein Assay 
(Biorad Inc., Hercules, CA, USA).
Streptavidin coated bridging ELISA
    Streptavidin-coated 96-well microplates or 8-well strips 
(Pierce, Rockford, IL, USA) were washed twice with PBST. 
After washing, 1 μg/ml of BIO-EPO was added to each well 
and incubated for 1 hour at RT. After incubation, plates 
were washed 3 times in a microplate washer (Molecular 
Devices, Inc., Sunnyvale, CA, USA) or manually. 1:5 di-
luted serum samples were mixed with an equal volume of 
40 ng/ml of digoxigenylated-EPO (DIG-EPO) in PBSAT 
and this mixture was added to wells and incubated for 2 
hours at RT. After incubation, plates were washed 3 times 
and anti-DIG Fab-HRP conjugate (Roche, Mannheim, 
Germany) diluted in PBSAT was added to each well and 
then incubated for 1 hour. After washing, ABTS solution 
was added to each well and incubated. Optical density was 
measured at 405 nm (reference wavelength: 492 nm).
Immunoprecipitation and immunoblotting
    For immunoblotting, serum was incubated with 2 μg/ml 
of recombinant EPO together with 20 μl of protein A/G 
PLUS agarose (Santa Cruz biotechnology, Santa Cruz, 
CA, USA) in a total volume of 1 ml PBSAT for overnight 
with continuous rocking at 4oC. Agarose beads were pel-
leted by centrifugation, washed three times in PBSAT, and 
reconstituted in 20 μl of PBSAT. EPO were removed from 
the beads by boiling in a 6x sample loading buffer and 
electrophoresed under reducing conditions in 12% poly-
acrylamide gels and then transferred to a nitrocellulose 
membrane. Nonspecific binding was inhibited by in-
cubation in blocking buffer (20 mM Tris, pH 7.4-buffered 
saline with 0.1% Tween 20 containing 5% nonfat dried 
milk) for 1 h. Rabbit polyclonal antibody (Epo (H-162), 
Santa Cruz biotechnology, Santa Cruz, CA, USA) were ex-
posed to membranes for 90 min at a dilution of 1:200. After 
washing, the blots were incubated for 1 h with horseradish 
peroxidase-conjugated anti-rabbit IgG at a dilution of 1: 
10,000 and detected with the chemiluminescent substrate 
(Pierce, Rockford, IL, USA) for 1 min according to the man-
ufacturer’s instructions and visualized with X-ray film. 
Densitometric analysis was performed with TINA software 
(Raytest, Straubenhardt, Germany).
RESULTS
False positives were occurred frequently in conventional 
ELISA which was developed for the detection of anti-EPO 
binding Abs
    Because conventional ELISA is relatively easy to set up 
and has been used for long time, we initially tried to setup 
this assay for the purpose of detecting anti-EPO Abs in hu-
man sera. Anti-EPO Abs in serum samples were bound to 
recombinant human EPO which was directly immobilized 
to plate wells and detected by enzyme-conjugated secon-
dary Ab. Sixty-eight serum samples were applied to this 
assay and the data were shown in Fig. 1. Throughout the 
whole samples, background level was generally high and 
the mean OD value of normal control serum was 0.6 after 
incubation for 30 minutes. Six samples were well above 
the cut-off value (mean OD of normal control ×2) and ini-
tially regarded as positives for anti-EPO Abs. However, the 
binding was turned out to be non-specific because the Abs 
interacted with the control antigen of bovine serum albu- 
min (BSA) as well as to EPO (Fig. 2A). Single dilutions 
(1/50) of six serum samples were compared in EPO or 
BSA binding. The OD values of the binding of two samples 
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Fig. 3. Screening of serum samples with bridging ELISA. For performing directly coated bridging ELISA (A), plates were coated with 1
μg/ml of EPO and blocked with PBSA. 1:5 diluted serum samples were mixed with an equal volume of 300 ng/ml of BIO-EPO and this
mixture was added to wells. After incubation, streptavidin-HRP conjugate was added to each well. After washing, ABTS solution was 
added to each well and incubated. Optical density was measured at 405 nm (reference wavelength: 492 nm). Rabbit polyclonal 
anti-EPO Ab was used as positive control. PC is for positive control, NC is for normal control, and BK is for blank. For performing 
streptavidin coated bridging ELISA (B), streptavidin-coated 96-well microplates or 8-well strips were added by 1 μg/ml of BIO-EPO. 
After incubation, 1:5 diluted serum samples were mixed with an equal volume of 40 ng/ml of DIG-EPO and this mixture was added to 
wells. After incubation, anti-DIG Fab-HRP conjugate was added to each well. After washing, ABTS solution was added to each well and 
incubated. Optical density was measured at 405 nm (reference wavelength: 492 nm). PC is for positive control and BK is for blank.
Fig. 2. Non-specific binding of human 
serum samples. ELISA plates were 
coated with 1 μg/ml of EPO or BSA. 
The plates were blocked and serum 
samples (#1, 18, 44, 52, and 63) 
diluted at 1:50 (A) or serial dilution of 
sample P44 (B) were added. Following 
procedure was described in Fig. 1.
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Fig. 4. Immunoprecipitation and immunoblot analysis of interaction between #63 and EPO. Blank (BK, without serum), normal 
control serum (NC), patients’ sera (#18, #63, #44) were bound to EPO and immunoprecipated with protein A/G. EPO was 
recovered from the beads and electrophoresed under reducing conditions in 12% polyacrylamide gels and then transferred to a 
nitrocellulose membrane. EPO was detected by using rabbit polyclonal antibody and horseradish peroxidase-conjugated anti- 
rabbit IgG (A). Densitometric analysis of EPO band was shown on the right side of images (B).
(#1, #44) to BSA were even higher than to EPO. To con-
firm the non specificity of serum samples more closely, se-
rially diluted samples were applied to EPO and BSA coat-
ed microplates (Fig. 2B). The binding of #44 to BSA was 
comparable to EPO and dose-dependent.
All the samples were negative for EPO binding in directly 
coated bridging ELISA
    To reduce the background signals obtained from con-
ventional ELISA, we used the directly coated bridging 
ELISA to overcome this problem. Anti-EPO Abs in serum 
samples bridged BIO-EPO to EPO which directly immobi-
lized to plate wells. Serum samples were applied to this as-
say and data were shown in Fig. 3A. Clearly, almost OD 
values were under 0.2 after incubation for 30 minutes. 
Even six samples which showed high activity of EPO bind-
ing in the conventional ELISA were not positive at all. 2 
μg/ml of rabbit polyclonal anti-EPO Ab was used as pos-
itive control.
One sample was positive for EPO binding in streptavidin 
coated bridging ELISA
    Very sensitive and selective method of streptavidin 
coated bridging ELISA was reported (Hoesel et al., 2004). 
In order to confirm the results of directly coated bridging 
ELISA, we screened all the samples again with this assay. 
To setup streptavidin coated bridging ELISA, additional la-
beling of EPO, DIG conjugation to EPO (DIG-EPO), was 
required. Anti-EPO Abs in serum samples bridged DIG- 
EPO to BIO-EPO which bound to streptavidin coated plate 
wells. Serum samples were applied to this assay and the 
data were shown in Fig. 3B. Only OD value of #63 sample 
was significantly higher than the other samples. Reference 
material was mouse monoclonal anti-EPO Ab and stand-
ard curve was made with this. The concentration of an-
ti-EPO Abs in #63 sample was 384.1 ng/ml all the other 
samples were 0 ng/ml.
Reactivity of #63 sample to EPO was confirmed by 
pull-down assay
    The presence of anti-EPO Abs in #63 serum sample 
was further demonstrated by pull-down assay. Human 
sample #18 and #44 which showed high nonspecific sig-
nals in conventional ELISA were chosen as controls. Each 
serum sample was incubated with recombinant EPO and 
precipitated by protein A/G beads. Then EPO was eluted 
from beads and separated by SDS-PAGE and detected by 
western blotting. EPO protein band was only appeared in 
#63 sample (Fig. 4A). Densitometric analysis of EPO blot 
was showed in Fig.4B. Non-specific antibody bands also 
appeared in all samples.
DISCUSSION
    Ab-associated PRCA is a rare but life threatening ad-
verse event occurred in CKD patients undergoing EPO 
administration. Therefore universal standardized assay is 
required for detection of anti-EPO Abs in patient serum. 
ELISA method has been widely used due to its properties 
of easiness and high throughput. However, it has been in-
dicated that some ELISAs may not have some level of sen-
sitivity and specificity for detection of low levels of EPO 
specific Abs (Thorpe and Swanson, 2005a).
    Initially, by using conventional ELISA, clinical serum 
samples from CKD patients were screened to detect the 
presence of anti-EPO Abs. This assay was convenient to 
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perform because no labeling of EPO was required and ex-
perienced previously in other cases. However, we ob-
tained false positive results with high background (Fig. 1). 
This phenomenon is probably due to some interfering se-
rum factors such as rheumatic factors (Hennig et al., 2000) 
and unknown sticky antibodies. Some samples showed 
slightly higher EPO-binding signals than BSA-binding and 
others showed significantly higher signals (Fig. 2A). Dose- 
dependent and comparable response to BSA as well as 
EPO and no substantial decrease of background despite 
multiple dilutions indicated that this signal is non-specific 
rather than EPO-specific (Fig. 2B). However, in case of 
#63, it showed much higher EPO-binding signals than 
BSA, therefore, further assays were needed to demon-
strate their specificity. In addition, considering the PRCA 
statistics of incidence rates of 0.02 to 0.03 per 10,000 pa-
tient-years (McKoy et al., 2008), this high rates (six per six-
ty eight) were certainly abnormal. Quantitative analysis 
was impossible with this assay because human anti-EPO 
standards are essential to this ELISA format but there are 
no available human standards.
    To overcome the non-specificity problem of conven-
tional ELISA, bridging format of ELISA was introduced. 
Bridging ELISA adopted dual recognition system, which 
ensures high specificity (Thorpe and Swanson, 2005b). 
EPO should be labeled with biotin to develop a directly 
coated bridging ELISA. Contrary to the data of conven-
tional ELISA, we found no positives for anti-EPO Abs and 
low backgrounds in serum samples (Fig. 3A). However, 
when we made a standard curve with rabbit polyclonal an-
ti-EPO Ab, we found this assay is not so sensitive (data not 
shown). Selectivity problem was solved but sensitivity 
problem still existed. So we searched more sensitive and 
selective one.
    Highly sensitive and selective method of streptavidin 
coated bridging ELISA was reported (Hoesel et al., 2004). 
They found that the method of EPO immobilization on 
plates is a critical determinant for the sensitivity of ELISA 
used for measuring anti-EPO Abs and streptavidin coated 
bridging ELISA results in a sensitivity of up to two orders 
magnitude higher than directly coated bridging ELISA 
(Gross et al., 2006). In addition, this assay has been shown 
to have very low backgrounds compared to the non-bridg-
ing conventional ELISA (Thorpe and Swanson, 2005b). 
We finally applied our serum samples to this assay and 
found only one outstanding anti-EPO positive sample 
(#63). Actually, #63 sample was one of the false positives 
with #1, 18, 44, and 52 in conventional ELISA.
    After performing the three kinds of ELISAs to measure 
the anti-EPO Abs in serum, we have found one case of an-
ti-EPO positive, #63. To test the interaction between EPO 
and #63 serum in solution state, EPO protein was mixed 
with #63 serum and protein A/G beads and incubated 
overnight. Precipitated EPO protein was revealed by 
SDS-PAGE and western blotting. Only #63 serum pre-
cipitated EPO protein and the other selected samples, 
which showed nonspecific signals in conventional ELISA, 
did not. 
    Although anti-EPO Ab was confirmed in patient #63, 
neutralizing assay and bone marrow biopsy will be re-
quired to diagnose PRCA. In addition, further kinetic mon-
itoring of anti-EPO Abs will be helpful to diagnose and treat 
this condition.
    In conclusion, we have found that streptavidin coated 
bridging ELISA was the most reliable assays among the 
popular three kinds of ELISA methods in terms of se-
lectivity and sensitivity as for the purpose of screening an-
ti-EPO Ab in human serum. 
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